Publications by authors named "Joyce F Liu"

53Publications

Clinical assays for assessment of homologous recombination DNA repair deficiency.

Gynecol Oncol 2020 Oct 2. Epub 2020 Oct 2.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.09.029DOI Listing
October 2020

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.

Gynecol Oncol 2020 Oct 6;159(1):72-78. Epub 2020 Aug 6.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.07.028DOI Listing
October 2020

Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.

Gynecol Oncol 2020 Oct 5;159(1):13-16. Epub 2020 Aug 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.06.502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405821PMC
October 2020

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.

Gynecol Oncol 2020 02 17;156(2):488-497. Epub 2019 Oct 17.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.09.021DOI Listing
February 2020

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.

Clin Cancer Res 2019 Sep 8;25(18):5458-5465. Epub 2019 May 8.

Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-19-1065DOI Listing
September 2019

Antibody-drug conjugates in gynecologic malignancies.

Gynecol Oncol 2019 06 28;153(3):694-702. Epub 2019 Mar 28.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.245DOI Listing
June 2019

Technology Applications: Use of Digital Health Technology to Enable Drug Development.

JCO Clin Cancer Inform 2018 12;2:1-12

Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874035PMC
December 2018

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.

Cell Rep 2018 12;25(11):2972-2980.e5

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183181
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.11.054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366450PMC
December 2018

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Int J Gynecol Pathol 2019 May;38(3):230-240

Department of Pathology, Women's and Perinatal Pathology Division (H.M.D., K.C.S., E.E.M., W.R.W., M.S.H., B.J.Q., K.R.L., C.P.C., G.L.M., M.R.N., B.E.H.) Division of Gynecologic Oncology and Reproductive Biology (M.G.M., J.F.L., C.F., N.H., R.S.B.), Brigham and Women's Hospital Department of Pathology, Beth Israel Deaconess Medical Center (M.G., J.L.H., D.I.L.) Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute (E.S., P.A.K., U.A.M.), Harvard Medical School, Boston, Massachusetts Department of Pathology, Duke University Medical Center, Durham, North Carolina (K.C.S.) Department of Gynecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark (K.M.J.) Department of Pathology, Stanford University, Stanford, California (B.E.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000513DOI Listing
May 2019

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

J Clin Oncol 2016 12 23;34(36):4345-4353. Epub 2016 Oct 23.

Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562430PMC
December 2016

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.

Oncoimmunology 2016 Mar 10;5(3):e1090075. Epub 2015 Dec 10.

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1090075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839340PMC
March 2016

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Curr Oncol Rep 2016 May;18(5):29

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0515-zDOI Listing
May 2016

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Expert Opin Investig Drugs 2016 16;25(5):597-611. Epub 2016 Mar 16.

a Cancer Therapy Evaluation Program , National Cancer Institute , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2016.1156857DOI Listing
December 2016

Bevacizumab in newly diagnosed ovarian cancer.

Lancet Oncol 2015 Aug 23;16(8):876-8. Epub 2015 Jun 23.

Gynecology Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00064-9DOI Listing
August 2015

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.

J Clin Oncol 2014 May 17;32(13):1287-9. Epub 2014 Mar 17.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.7299DOI Listing
May 2014

PARP inhibitors in ovarian cancer: current status and future promise.

Gynecol Oncol 2014 May 4;133(2):362-9. Epub 2014 Mar 4.

Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.02.039DOI Listing
May 2014

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Cancer Res 2014 Feb 23;74(4):1141-52. Epub 2013 Dec 23.

Authors' Affiliations: Department of Medical Oncology; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Harvard Medical School; Department of Pathology, Division of Cytogenetics; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Peter MacCallum Cancer Centre, East Melbourne; Department of Oncology, Peter MacCallum Cancer Centre; Departments of Pathology and Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517944PMC
February 2014

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.

Gynecol Oncol 2013 Nov 13;131(2):352-6. Epub 2013 Aug 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.08.006DOI Listing
November 2013

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Gynecol Oncol 2011 Oct 17;123(1):5-12. Epub 2011 Jun 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.05.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171572PMC
October 2011

Poly ADP-ribose polymerase inhibitors: science and current clinical development.

Curr Opin Oncol 2010 Nov;22(6):567-72

Women's Cancers Program, Medical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32833edbf8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855399PMC
November 2010

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.

Gynecol Oncol 2009 Dec 30;115(3):401-6. Epub 2009 Sep 30.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.08.023DOI Listing
December 2009

Interns' work hours.

N Engl J Med 2005 Feb;352(7):726-8; author reply 726-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJM200502173520718DOI Listing
February 2005

Asian American-white American differences in expressions of social anxiety: a replication and extension.

Cultur Divers Ethnic Minor Psychol 2002 Aug;8(3):234-47

Department of Psychology, University of Illinois at Urbana-Champaign, 603 East Daniel Street, Champaign, Illinois 61820, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1037/1099-9809.8.3.234DOI Listing
August 2002